Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed.
It was a bad week for ketamine therapy patients as several firms cut back on operations, the biggest name being Field Trip.
Field Trip Health also moved to seek credit protection, its shares were suspended from trading, and CEO Ronan Levy resigns as part of restructuring.
This follows its recent announcement of clinic closings. What’s next for Field Trip Health?
Lucy Scientific will acquire intellectual property and related assets for Wesana’s psilocybin and cannabidiol (CBD) combination investigational therapy, SANA-013, as well as Wesana’s supply of psilocybin which is sufficient to complete all near-term clinical studies
In 2022, Wesana announced positive FDA feedback regarding SANA-103 and plans to develop a Phase 1b/2a human study for Major Depressive Disorder and other conditions.
Oregon Health Authority (OHA) has issued the state’s first psilocybin license as part of the nation’s first regulatory framework for psilocybin services. The manufacturer license was issued to Satori Farms.
The Oregon Psilocybin Services (OPS) is starting to award licenses to psilocybin facilitators, manufacturers, service centers, and laboratories. It began accepting applications on January 2, 2023 and expects to issue additional licenses in the coming months.
The Psychedelic Medicine PAC is a Political Action Committee intending to help elect leaders who believe in science and want to improve lives through psychedelic medicine.
President and Co-Founder and Chief Executive Officer of Psychedelic Medicine Coalition, Melissa Lavasani. “We believe it is time for the American people to take action into their own hands by electing leaders that support policies that expand access to these life-changing treatments. We look forward to working with policy leaders and organizations to create positive change and bring the benefits of psychedelic medicine to those in need.”
Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program
“Australia is an ideal location to advance the development of EB-373, as well as additional future therapies generated from our EVM201 and EVM301 Series, given the favorable clinical, regulatory and cost-saving opportunities available to biotechnology companies, particularly those advancing psychedelic-derived compounds for CNS conditions,” said Joseph Tucker, Ph.D., Director and CEO of Enveric Biosciences. “With the establishment of Enveric Therapeutics Pty. Ltd., we now have a foothold in Australia that we expect will enable us to efficiently and expeditiously advance our lead program towards generating human data by early 2024.”
Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed
psilocybin ketamine psychedelic therapeutics therapy major depressive disorder depressive disorder shares trading field trip health field trip wesana health wesana fda
Law & Regulation3 days ago
Psilocybin study for bipolar depression encourages more research
LSD4 days ago
TECH HEAVY: The Magnificent Seven has suddenly become the Fantastic Four
Psilocybin3 days ago
Magic Mushroom Edibles: Everything to Know, from Chocolates to Drops
Ketamine3 days ago
Prepping the psychedelic industry for MDMA approval
Psychedelics3 days ago
Psychedelics Effects on Sexual Functions
Law & Regulation2 days ago
Enveric sells cannabis patents to focus on psilocin candidates